Since the first discovery of its oncogenic kinase domain mutations [1,2], EGFR has been considered a key oncodriver for many tumor types, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) [3]. Here, EGFR is linked to non-small cell lung carcinoma.